VIZZ now commercially available in the US

Following a US Food and Drug Administration approval back in July 2025, LENZ Therapeutics has announced that VIZZ (aceclidine ophthalmic solution) 1.44% is now commercially available.¹ The first and only FDA-approved aceclidine-based eye drop is for the treatment of presbyopia in adults, with its professional product sample distribution having already begun nationally for optometrists and ophthalmologists, according to a news release.

Commercial product shipments will be initiated for patients in October through LENZ’s ePharmacy partner and is anticipated to be available in commercial locations such as retail pharmacies by the middle of Q4 this year, the release stated.¹

"We are thrilled to introduce VIZZ to the 128 million adults living with blurry near vision in the United States," said Eef Schimmelpennink, president and CEO of LENZ Therapeutics, in the release. "The team has been preparing for this moment for months and worked tirelessly to enable the availability of product samples and commercial product following our FDA approval. Initial feedback and early brand awareness from the ECP community is extremely positive, and we feel well-positioned for a successful product launch, firmly establishing VIZZ as a Category of One for the treatment of presbyopia."

VIZZ’s mechanism of action is lies in its predominantly pupil-selective miotic that works with the iris by minimal ciliary muscle stimulation. The drop contracts the iris sphincter muscle, which creates a pinhole effect with a sub-2mm pupil. This then extends the depth of focus achieved by the eye to improve near vision without causing a myopic shift, the company stated.¹

"With VIZZ now available, we're giving people living with presbyopia a simple, fast-acting way to see up close again," said Shawn Olsson, chief commercial officer of LENZ Therapeutics, in the release. "It's about restoring everyday confidence, including reading a phone, checking a price tag, or enjoying your active lifestyle glasses-free. We're excited to bring this new option to millions who want more freedom in their near vision."

Upon FDA approval, Marc Bloomenstein, OD, FAAO, clinical investigator for the Clarity clinical trial series, stated, “This is that ‘and’ we get to offer,” Bloomenstein said. “We now have a new option that may allow patients to get out there and do the things they want to do without thinking about contacts or spectacles.”²

References:

1. LENZ Therapeutics announces commercial product availability of VIZZ in the United States. News release. PR Newswire. September 30, 2025. Accessed September 30, 2025. https://www.prnewswire.com/news-releases/lenz-therapeutics-announces-commercial-product-availability-of-vizz-in-the-united-states-302570157.html

2. Bloomenstein MR. Another drop in the presbyopia bucket: Dr Bloomenstein shares his excitement for the FDA approval of Vizz. Optometry Times. August 6, 2025. Accessed September 30, 2025. https://www.optometrytimes.com/view/another-drop-in-the-presbyopia-bucket-dr-bloomenstein-shares-his-excitement-for-the-fda-approval-of-vizz